LifeStance Health Group, Inc. - LFST STOCK NEWS

A LifeStance Health survey reveals widespread election-related anxiety among Americans, with 79% experiencing anxiety over the 2024 U.S. presidential election. Key findings include:

• Younger generations are more likely to experience moderate to significant election-related anxiety
• 57% think about the election daily
• 60% of respondents in therapy discuss politics during sessions
• 44% report conflicts in personal relationships due to political discussions
• 33% would not date someone with opposing political views
• 72% say social media and news coverage contribute to election anxiety

The survey underscores the need for accessible mental healthcare to help people navigate election-related stress and maintain overall well-being. Dr. Ujjwal Ramtekkar, Chief Medical Officer at LifeStance, emphasizes the importance of mental health care in managing daily life stressors and building long-term resilience.

LifeStance Health Group (NASDAQ: LFST), a leading outpatient mental health care provider, has announced its participation in the 22nd Annual Morgan Stanley Global Healthcare Conference in New York City. The company's CFO, Dave Bourdon, will present on Wednesday, September 4, 2023, at 10:00 a.m. Eastern time. The presentation will be moderated by Craig Hettenbach.

Investors and interested parties can access the live webcast of the presentation through the Events and Presentations section of LifeStance Health's Investor Relations website. A replay of the webcast will also be available after the event concludes. This conference provides LifeStance an opportunity to showcase its position in the mental health care sector and update investors on its business strategies and performance.

LifeStance Health Group (Nasdaq: LFST) reported strong Q2 2024 results, with revenue increasing 20% to $312.3 million. The company's clinician base grew 14% to 6,984, and visit volumes rose 15% to 2.0 million. Despite a net loss of $23.3 million, Adjusted EBITDA improved significantly to $28.6 million, up 103% year-over-year.

LifeStance raised its full-year 2024 guidance, now expecting revenue between $1.2 billion to $1.242 billion, Center Margin of $363 million to $383 million, and Adjusted EBITDA of $90 million to $100 million. The company also reiterated expectations for positive Free Cash Flow for the year.

LifeStance Health's recent survey of 1,085 U.S. adults reveals critical insights into mental health care access and priorities. Key findings include:

1. 70% of respondents reported experiencing mental health challenges, with 64% having sought therapy previously.
2. 66% found therapists accepting their insurance, while 27% struggled to find in-network providers.
3. 65% couldn't afford therapy without insurance coverage.
4. 54% ranked therapy as their top discretionary expense.
5. 50% would choose free therapy over luxury experiences like cruises or concert tickets.

The survey also highlighted social media's role in mental health information, with YouTube being the most popular platform overall, while TikTok ranked highest among Gen Z users despite being considered potentially harmful.

LifeStance Health Group, Inc. (NASDAQ: LFST), a leading provider of outpatient mental health care in the United States, has announced its plans to release second quarter 2024 earnings before the market opens on Thursday, August 8, 2024. The company will host a live earnings conference call on the same day at 8:30 a.m. Eastern Time to discuss the results.

Interested parties can participate in the call by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and using the conference ID 1488997. A real-time audio webcast will be available on the LifeStance Investor Relations website, where related materials will be posted prior to the call. A replay of the webcast will also be accessible after the conference call concludes.

LifeStance Health Group (NASDAQ: LFST), a leading provider of outpatient mental health care in the U.S., announced its participation in two upcoming investor conferences. CFO Dave Bourdon and VP of Finance and Investor Relations Monica Prokocki will attend the UBS Healthcare Services Cape Cod Summit on June 4, 2024, in Chatham, MA, and the Goldman Sachs 45th Annual Healthcare Conference on June 10, 2024, in Miami Beach, FL. While the Cape Cod event will not include presentations, the Goldman Sachs conference will feature a presentation at 10:00 a.m. ET, which will be webcast live and later available for replay on LifeStance’s Investor Relations website.

LifeStance Health Group announced the pricing of a secondary public offering of 20,000,000 shares at $6.25 per share. The underwriters have a 30-day option to purchase an additional 3,000,000 shares. Proceeds will go to the selling stockholders, with none to LifeStance. The offering is expected to close by May 24, 2024, subject to customary conditions. The transaction is facilitated by major financial institutions including Morgan Stanley and Goldman Sachs. The shelf registration statement was filed with the SEC and became effective on May 21, 2024.

LifeStance Health Group announced a secondary public offering of 20 million shares of common stock by certain stockholders. The underwriters are given a 30-day option to purchase an additional 3 million shares. LifeStance will not sell any shares or receive any proceeds from this offering. The offering is made under a shelf registration statement filed with the SEC on May 21, 2024. Morgan Stanley, Goldman Sachs & TPG Capital are the underwriters. The prospectus is available on the SEC's website.

LifeStance Health Group, Inc. (Nasdaq: LFST) reported strong financial results for Q1 2024, with a revenue increase of 19% to $300.4 million, driven by higher visit volumes and improved revenue per visit. The clinician base also grew by 15%, reaching 6,866 clinicians. The company posted a net loss of $21.1 million, attributed to stock-based compensation, and an Adjusted EBITDA of $27.7 million. LifeStance reiterated its full-year revenue guidance of $1.19 billion to $1.24 billion, raising Center Margin expectations to $353 to $373 million, and Adjusted EBITDA to $88 to $98 million. The company also expects to maintain positive Free Cash Flow for the year.